WEST CHESTER, Ohio--(EON: Enhanced Online News)--AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced that it will be participating in the following upcoming investor conferences:
- The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin Grand Central Hotel in New York on November 14, 2013.
- The Piper Jaffray 2013 Annual Health Care Conference at the New York Palace Hotel on December 4, 2013.
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy Ablation System is the first and only device approved by the Food and Drug Administration (FDA) for the surgical treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left Atrial Appendage (LAA) occlusion device is the most widely implanted device for LAA management worldwide. Afib affects more than two million people worldwide and is estimated to cost more than $6.5 billion annually in healthcare expenses. The number affected by Afib is expected to grow to 12 million by 2050.